Neoadjuvant, Adjuvant Pembrolizumab Beneficial in Resectable Melanoma
FRIDAY, March 10, 2023 (HealthDay News) -- For patients with resectable stage III or IV melanoma, event-free survival is longer for those receiving neoadjuvant and adjuvant pembrolizumab compared with those receiving only adjuvant pembrolizumab, according to a study published in the March 2 issue of the New England Journal of Medicine.
Sapna P. Patel, M.D., from the University of Texas M.D. Anderson Cancer Center in Houston, and colleagues randomly assigned patients with clinically detectable, measurable stage IIIB to IVC melanoma that was amenable to surgical resection to three doses of neoadjuvant pembrolizumab, surgery, and 15 doses of adjuvant pembrolizumab (neoadjuvant-adjuvant group) or to surgery followed by pembrolizumab every three weeks for 18 doses (adjuvant-only group; 154 and 159 patients, respectively).
The researchers found that the neoadjuvant-adjuvant group had significantly longer event-free survival than the adjuvant-only group at a median follow-up of 14.7 months. Event-free survival at two years was 72 and 49 percent in the neoadjuvant-adjuvant group and the adjuvant-only group, respectively, in a landmark analysis. The percentage of patients with treatment-related adverse events of grades 3 or higher was 12 and 14 percent in the neoadjuvant-adjuvant and adjuvant-only groups, respectively.
"These data add to the body of knowledge supporting the use of neoadjuvant therapy in oncology," the authors write.
The study was funded in part by Merck, the manufacturer of pembrolizumab.
Abstract/Full Text (subscription or payment may be required)
Related Posts
Thousands of U.S. Kids Have Died Riding ATVs, Many More Sent to ERs
MONDAY, Sept. 26, 2022 (HealthDay News) -- Pediatric surgeon Dr. Rony Marwan has...
The Different Types of Depression, Explained
TUESDAY, May 16, 2023 (HealthDay News) -- An estimated 5% of adults worldwide...
Flu Boosts Short-Term Odds for Heart Attack 6-Fold
WEDNESDAY, March 29, 2023 (HealthDay News) -- Getting the flu isn’t fun for many...
Pfizer Says Lower Dose of Its COVID-19 Vaccine Protects Younger Children
FRIDAY, Oct. 22, 2021 (HealthDay News) -- A lower dose of the Pfizer COVID-19...